A real life study assessing gender related differences in safety after switching to BICTEGRAVIR/TAF/FTC
Latest Information Update: 28 Dec 2021
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
Most Recent Events
- 28 Dec 2021 New trial record
- 30 Oct 2021 Results presented at the 18th European AIDS Conference